WHITE PAPER: The Future of Diagnostics for Immuno-oncology

Executive Summary:

  • The explosion of immuno-oncology (I/O) therapies has created a complicated, dynamic, and competitive landscape that is focused on patient selection for drug efficacy and differentiation.
  • Understanding both immune content and immune context is critical for differentiating patient response to enable a patient selection strategy.
  • A novel Computational Tissue Analysis (cTA™) platform can deliver data-rich tissue context information to support I/O drug development and provide clarity to diagnostic decisions, despite the complexity of tissue biomarkers.
  • The use of standard immunohistochemistry (IHC) assays and standard slide scanning to support cTA-based diagnostics simplifies the approach and provides for a clear regulatory pathway.
Share This Post: